TY  - JOUR
TI  - An Overview of Adenovirus Vector-based Vaccines against SARS-CoV-2
SP  - 12
SN  - 2322-4568
EP  - 25
N1  - Virology and Infectious diseases units at Parasitology and Animals Diseases, National Research Centre, Dokki, 33 Bohouth Street, Giza, 12622, Egypt; Virology Department, Central Public Health Laboratories, Ministry of Health and Population, Cairo, Egypt; Tropical Medicine, Gastroenterology and Hepatology-Digestive Endoscopy at Complementary Medicine Department, Medical Research Institute, National Research Centre, Dokki,33 Bohouth Street, Giza, 12622, Egypt; Clinical and Chemical Pathology Department, Medical Research Institute, National Research Centre, Dokki,33 Bohouth Street, Giza, 12622, Egypt; Virology Department, Animal Health Research Institute (AHRI), Dokki,Nadi El-Said Street, Giza, Egypt
KW  - ad 26 cov 2 s; adenovirus vector; angiotensin converting enzyme 2; bnt 162b 2; coronavac; covilo; hemagglutinin; ibacovavec; SARS-CoV-2 vaccine; sputnik v vaccine; tozinameran; vaxzevria; virus spike protein; zorecimeran
KW  -  Adenoviridae; adenovirus infection; Article; chimpanzee; coronavirus disease 2019; drug efficacy; drug safety; hemagglutination; human; immune response; immunogenicity; nonhuman; Severe acute respiratory syndrome coronavirus 2; viral tropism; virus strain
AV  - public
A1  - Zeedan, G.S.G.
A1  - Abdalhamed, A.M.
A1  - Naguib, A.M.
A1  - Shalaby, S.I.A.
A1  - Awad, M.A.M.
A1  - El Moniem, M.I.A.
IS  - 1
PB  - Scienceline Publication, Ltd
JF  - World's Veterinary Journal
VL  - 13
Y1  - 2023/03/25/
ID  - eprints814
N2  - Adenovirus vectors have been employed to develop a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for curtailing the Covid-19 pandemic spreading. Many different viral vectors have been mainly targeting the SARS-CoV-2 spike (S) protein as an antigen. Spike (S) protein is comprised of S1 and S2 subunits, in which the receptor-binding domain (RBD) of S1 is responsible for recognizing and engaging with its host cellular receptor protein angiotensin-converting enzyme 2 (ACE2), S2 accounts for membrane fusion of virus and host cell. Chimpanzee adenovirus was also used as a vector vaccine for SARS-CoV-2 (ChAdSARS-CoV-2-S) by intramuscular injection, and intranasal administration has been tested. Adenovirus vector-based vaccines are the most advanced, with several vaccines receiving Emergency Use Authorization (EUA). It was shown that rhesus macaques were protected from SARS-CoV-2 challenge after a month of being vaccinated with ChAd-SARS-CoV-2-S. A single intranasal or two intramuscular ChAd-SARSCoV-2-S vaccines could induce humoral antibodies and T cell responses to protect the upper and lower respiratory tract against SARS-CoV-2. As the effectiveness was demonstrated in non-human primates, ChAd-SARS-CoV-2-Sa potential option for preventing SARS-CoV-2 infection in humans. However, detecting novel more transmissible and pathogenic SARS-CoV-2 variants added concerns about the vaccine efficacy and needs monitoring. Moreover, the cause of recently documented rare cases of vaccine indicated immune thrombotic thrombocytopenia. This review article provided details for the adenovirus vector vaccine for SARS-CoV-2 in humans and tried to provide solutions to the adenovirus vector hemagglutinin issue © 2023, World's Veterinary Journal.All Rights Reserved.
UR  - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151913612&doi=10.54203%2fscil.2023.wvj2&partnerID=40&md5=71907b5ad05b574467e58153a2ecb859
ER  -